From this perspective, the raise of RANK-positive CTCs in patients who have obtained the higher skeletal benefit, may reflect the ability of denosumab to effectively disrupt RANKL/RANK signaling leading to reduction of cancer cell retention in bone and, hence, a paradoxical release of RANK-positive CTCs in bloodstream. Here, TNFRSF11A is linked to cancer.